Estimating the prevalence of hepatitis delta virus infection among adults in the United States: A meta‐analysis
Liver International · 2024-07 · 44 (7) · 1715-1734
DOI: 10.1111/liv.15921 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Liver International, online erschienen am 02.04.2024. Verfasst von Robert J Wong und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, California, USA. Hauptthemen laut MEDLINE: Hepatitis Delta Virus, Hepatitis D. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
Background and Aims Suboptimal awareness and low rates of hepatitis delta virus (HDV) testing contribute to underdiagnosis and gaps in accurate estimates of U.S. HDV prevalence. We aim to provide an updated assessment of HDV prevalence in the U.S. using a comprehensive literature review and meta‐analysis approach.
Methods
A comprehensive literature review of articles reporting HBsAg seroprevalence and anti‐HDV prevalence was conducted to calculate country‐specific rates and pooled prevalence of CHB and HDV using meta‐analyses. Country‐specific CHB and HDV rate estimates were combined with number of foreign‐born (FB) persons in the U.S. in 2022 from U.S. Census Bureau to estimate total numbers of FB with CHB and HDV, respectively. These estimates were further combined with updated estimates of U.S.‐born persons with CHB and HDV to yield the total number of persons with CHB and HDV.
Results
In 2022, we estimated 1.971 million (M) (95% CI 1.547–2.508) persons with CHB; 1.547 M (95% CI 1.264–1.831) were FB and 0.424 M (95% CI: 0.282–0.678) were U.S.‐born. The weighted average HDV prevalence among FB persons in the U.S. was 4.20% (64 938 [95% CI 33055–97 392] persons), among whom 45% emigrated from Asia, 25% from Africa, and 14% from Europe. When combined with updated estimates of U.S.‐born persons with HDV, we estimate 75 005 (95% CI: 42187–108 393) persons with HDV in the U.S.
Conclusions
Including both FB and U.S.‐born persons, we estimated that 1.971 M and 75 005 persons were living with CHB and HDV, respectively, in the U.S. in 2022.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, California, USA.
- Gastroenterology Section, Veterans Affairs Palo Alto Healthcare System, Palo Alto, California, USA.
- Department of Medicine, Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
- S Wong Consulting, LLC, Mountain View, California, USA.
- Toronto Centre for Liver Disease, University Health Network, Toronto, Ontario, Canada.
- Department of Medicine, Aga Khan University, Karachi, Pakistan.
ORCID-Profile: Robert J Wong, Jordan Feld, Saeed Hamid, Heiner Wedemeyer, Robert Gish
Förderung
- Gilead Sciences
Zitieren
APA
Wong, R. J., Brosgart, C., Wong, S. S., Feld, J., Glenn, J., Hamid, S., Cohen, C., Zovich, B., Ward, J., Wedemeyer, H., Yurdaydin, C., & Gish, R. (2024). Estimating the prevalence of hepatitis delta virus infection among adults in the United States: A meta‐analysis. Liver International, 44(7), 1715-1734. https://doi.org/10.1111/liv.15921
Vancouver
Wong RJ, Brosgart C, Wong SS, Feld J, Glenn J, Hamid S, et al. Estimating the prevalence of hepatitis delta virus infection among adults in the United States: A meta‐analysis. Liver International. 2024;44(7):1715-1734. doi:10.1111/liv.15921
BibTeX
@article{Wong2024,
author = {Wong, Robert J and Brosgart, Carol and Wong, Steven S and Feld, Jordan and Glenn, Jeffrey and Hamid, Saeed and Cohen, Chari and Zovich, Beatrice and Ward, John and Wedemeyer, Heiner and Yurdaydin, Cihan and Gish, Robert},
title = {Estimating the prevalence of hepatitis delta virus infection among adults in the United States: A meta‐analysis},
journal = {Liver International},
year = {2024},
volume = {44},
number = {7},
pages = {1715--1734},
doi = {10.1111/liv.15921}
}
EUVIMED